In 2023, Kenya-based pharmaceutical institution Universal Corporation Ltd became the archetypal African shaper to person World Health Organisation (WHO) prequalification to nutrient tenofovir disoproxil fumarate, lamivudine and dolutegravir (TLD) – a first-line antiretroviral therapy for HIV.